1771MO Pembrolizumab (pembro) plus enzalutamide (enza) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Randomized double-blind phase III KEYNOTE-641 study

Julie N. Graff, Mauricio Burotto, Peter C.C. Fong, David Pook, B. Zurawski, Ray Manneh Kopp, Judith Salinas, Kathryn Bylow, Gero Kramer, Raffaele Ratta, Mariusz Kwiatkowski, Margitta Retz, Cheol Kwak, Jóse Ángel Arranz Arija, Howard Gurney, Nobuaki Matsubara, Li Liang, Jelena Todoric, Kentaro Imai, Arnulf Stenzl